Summary: When combined, two drugs from Novartis and Pfizer doubled the time that post-menopausal women with a type of advanced breast cancer lived without their disease getting worse. The combination had progression free survival of as much as seven months more than women treated with the Pfizer drug alone.
Critique: I think that this is awesome. Maybe with a little more work, scientists will be able to extend that seven months.
Impact: A lot of scientists are saying that this is really significant. However, many breast cancer patients, and almost all of them with advanced forms of the disease become resistant to hormonal therapy. I think that this treatment may help some people, but it won't help others. Although I think that it's worth trying.
Reference: http://www.foxnews.com/health/2011/09/26/novartiss-afinitor-shows-promise-in-breast-cancer/
No comments:
Post a Comment